GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » ViaDerma Inc (OTCPK:VDRM) » Definitions » Earnings Yield (Joel Greenblatt) %

ViaDerma (ViaDerma) Earnings Yield (Joel Greenblatt) % : 0.00% (As of Jun. 2012)


View and export this data going back to 2008. Start your Free Trial

What is ViaDerma Earnings Yield (Joel Greenblatt) %?

ViaDerma's Enterprise Value for the quarter that ended in Jun. 2012 was $7.12 Mil. ViaDerma's EBIT for the trailing twelve months (TTM) ended in Jun. 2012 was $3.76 Mil. ViaDerma's Earnings Yield (Joel Greenblatt) for the quarter that ended in Jun. 2012 was 0.00%.

The historical rank and industry rank for ViaDerma's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:

VDRM's Earnings Yield (Joel Greenblatt) % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 2.36
* Ranked among companies with meaningful Earnings Yield (Joel Greenblatt) % only.

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. ViaDerma's Forward Rate of Return (Yacktman) % for the quarter that ended in Jun. 2012 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past seven years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.


ViaDerma Earnings Yield (Joel Greenblatt) % Historical Data

The historical data trend for ViaDerma's Earnings Yield (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ViaDerma Earnings Yield (Joel Greenblatt) % Chart

ViaDerma Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11
Earnings Yield (Joel Greenblatt) %
- 212.77 9.49 68.03 47.62

ViaDerma Quarterly Data
Sep07 Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12
Earnings Yield (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 54.05 47.62 54.95 -

Competitive Comparison of ViaDerma's Earnings Yield (Joel Greenblatt) %

For the Drug Manufacturers - Specialty & Generic subindustry, ViaDerma's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ViaDerma's Earnings Yield (Joel Greenblatt) % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, ViaDerma's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where ViaDerma's Earnings Yield (Joel Greenblatt) % falls into.



ViaDerma Earnings Yield (Joel Greenblatt) % Calculation

In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.

ViaDermas Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2011 is calculated as

Earnings Yield (Joel Greenblatt)=EBIT/Enterprise Value
=4.049/7.125464
=56.82 %

ViaDerma's EBIT for the trailing twelve months (TTM) ended in Jun. 2012 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.76 Mil.



ViaDerma  (OTCPK:VDRM) Earnings Yield (Joel Greenblatt) % Explanation

Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.

Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.


Be Aware

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

Forward Rate of Return (Yacktman) % based on Don Yacktman's definition is a better measure of the expected rate of return for a stock.


ViaDerma Earnings Yield (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of ViaDerma's Earnings Yield (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


ViaDerma (ViaDerma) Business Description

Industry
Traded in Other Exchanges
N/A
Address
4640 Admiralty Way, Suite 500, Marina Del Rey, CA, USA, 90292
ViaDerma Inc is a specialty pharmaceutical company focused to bring new products to market through research and development. It is engaged in the business of manufacturing and sales of pharmaceuticals, and specifically topical antibiotics and pain management in the United States of America. Its sells under the brand name Vitastem. The Company also has products in development in the fields; anti-aging skin care, pain management, hair-loss, and toenail fungus.

ViaDerma (ViaDerma) Headlines

From GuruFocus

ViaDerma Provides an Update on Current & Future Business Activities

By sperokesalga sperokesalga 03-02-2023

ViaDerma, Inc. Provides a Corporate Update

By GlobeNewswire GlobeNewswire 01-16-2020

ViaDerma Inc., Provides Review of 2020 and Looks Forward to 2021

By Marketwired Marketwired 01-13-2021

ViaDerma, Inc. Provides a Corporate Update

By Marketwired Marketwired 06-23-2020

ViaDerma, Inc. Nearing Initial Order from Large Hospital Network

By Marketwired Marketwired 05-13-2021

ViaDerma, Inc. Provides an Update on its Current Marketing Efforts

By Marketwired Marketwired 08-27-2020

ViaDerma, Inc. Provides a Corporate Update

By Marketwired Marketwired 01-16-2020